Precision is also paramount in terms of getting optimal treatment for people, and the appeal of different treatments might differ amongst people. GLP-1 Treatments Face Hurdles While GLP-1s offer promising benefits for some patients, significant barriers remain regarding supply, cost, and insurance coveragechallenges that Saunders describes as humongous limitations. Novo Nordisks Ozempic and Wegovy have been on the FDAs drug shortage list since 2022
Like all GLP-1 medications, the Wegovy pill (oral semaglutide) can cause side effects, particularly during early treatment or when doses change
Mann-Whitney for continuous variables
Drug compounding is a well-established practice
In the phase II dose-ranging study discussed previously, patients receiving larger doses of semaglutide (i.e., 40 mg vs
Exp Eye Res 2023;232:109496